Comparison of p53 and prohibitin expression in the spectrum of hepatitis, cirrhosis, and hepatocellular carcinoma

Lívia Maria Della Porta¹, Fernando Silva Ramalho¹, Carlos Augusto Oliveira², Deisy Mara Silva¹, Marlei Josiele Augusto¹, Leandra Náira Zambelli Ramalho¹

¹Department of Pathology and Legal Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil. ²Department of Food Engineering, School of Animal Science and Food Engineering, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Correspondence to: Dr. Leandra Náira Zambelli Ramalho, Department of Pathology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil. E-mail: lramalho@fmrp.usp.br


Aim: To investigate the correlation of p53 and prohibitin (PHB) expression in the spectrum of hepatitis, cirrhosis, and human hepatocellular carcinoma (HCC).

Methods: Hepatic biopsies from patients with HCC (n = 60), cirrhosis (CIR, n = 30), hepatitis C virus (HCV, n = 30), and normal livers (NL, n = 20) were examined for immunohistochemical expression of RelA/p65, tumor necrosis factor receptor-1 (TNFR1), TNF-related apoptosis-inducing ligand (TRAIL), p53, and PHB. The samples were also analysed by nuclear factor kappa B (NFκB) Southwestern histochemistry and a transferase-mediated dUTP-biotin nick-end labelling assay.

Results: Expression of NFκB and RelA/p65 was detected increasingly from NL to CIR, but had a diminished labelling in the HCC cases (P < 0.05). Expression levels of TNFR1 and TRAIL followed the same pattern (P < 0.05). Apoptosis was increased in HCC, but was progressively reduced from CIR to NL (P < 0.05). p53 and PHB nuclear expressions were amplified in cases of HCC, but diminished in NL, HCV, and CIR (P < 0.05).

Conclusion: These results suggest that in addition to well-understood sequences of proinflammatory events such as TNF-induced NFκB activation and NFκB/TRAIL pathway-mediated apoptosis, development of HCC is also influenced by regulation of p53 and PHB tumour suppressor function. Additional studies are necessary to explain the contradictory mechanisms of the tumour microenvironment observed in the sequence of HCV, CIR, and HCC.

Key words: p53, prohibitin, nuclear factor kappa B, apoptosis, hepatocellular carcinoma

INTRODUCTION

Hepatocellular carcinoma (HCC), the most frequent primary hepatic cancer, is the third highest cause of cancer-related death worldwide.¹ Accumulation of genetic and epigenetic alterations results in the development of HCC.² Therefore, the molecular pathways involved in hepatic cancer have been the focus of numerous studies.

Activation of the transcriptional factor nuclear factor kappa B (NFκB), an important modulator of inflammatory and cell survival responses,³ has been associated with hepatic carcinogenesis.⁴ NFκB may be activated in...
hepatocytes as a consequence of chronic inflammation, which occurs in viral hepatitis. However, little is known about the interaction of NFκB activation and tumour microenvironment in the sequence of hepatitis C virus (HCV), cirrhosis (CIR), and HCC.

The inflammatory cytokine tumor necrosis factor-α (TNFα) participates in the control of cellular proliferation and differentiation and cell death. Although TNFα was initially identified as inducing cell death in some tumours, an association between activation of the TNFα/NFκB pathway by inflammation and hepatocarcinogenesis has also been reported. Binding of TNFα to TNF receptor-1 (TNFR1) results in NFκB activation and may induce hepatocyte survival and proliferation. Additionally, activated NFκB can be considered as a protector of TNFα-induced apoptosis.

TNF-related apoptosis-inducing ligand (TRAIL) has been demonstrated as a proapoptotic mediator of various tumour cells. Similarly, TRAIL caused cytotoxic effects in transformed hepatocytes of HCC, perhaps related to inhibition of NFκB survival signalling. In contrast, participation of TRAIL in hepatocyte’s apoptosis during chronic hepatic diseases remains controversial.

The p53 gene is a classical tumor suppressor gene. p53 mutations occur in diverse human cancers, including HCC. p53 tumor suppressor function involves cell cycle control, transcriptional regulation, and apoptosis. In spite of the p53 mutation being rare in HCC not induced by aflatoxin, the high incidence of HCV-related HCC justifies novel studies even in this context. NFκB linked to HCV non-structural 5A (NS5A) protein inhibits the p53 tumor suppressor role and leads to cell survival and hepatocarcinogenesis.

Human prohibitin (PHB), a pleiotropic protein, was identified first as a potential tumour suppressor and has been implicated in cellular differentiation, antiproliferation, and morphogenesis. Although a liver-specific deletion of PHB has been observed in a wide spectrum of liver injury types, fibrosis, and hepatocarcinogenesis in mice, PHB has also been reported to be overexpressed in cases of human HCV. On the other handit has been suggested that PHB may have a pivotal role in cellular proliferation and malignant transformation. Thus, the role of PHB in development of human hepatic cancer remains controversial.

Our study aimed to compare the importance of the p53 and PHB pathway through the NFκB signalling in the spectrum of HCV, CIR, and HCC, considering the potential differences in the pathogenesis of human hepatic cancer.

METHODS

Tissue specimens
Primary liver carcinoma samples were obtained from the Department of Pathology at the University Hospital of the Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Twenty samples of normal liver from autopsies with causes other than liver disease (NL), 30 cases of HCV, 30 cases of CIR associated with HCV and 60 cases of HCC related to HCV-CIR were selected for this study [Table 1]. Patients with evidence of any other cause of liver disease were excluded. The study was approved by the local Ethics Committee (number 1611/2011).

Immunohistochemistry
Liver preparations were submitted for immunohistochemical analysis. Sections were incubated with monoclonal primary antibodies specific for TNFR1, TRAIL, RelA/p65, and p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, dilution 1:100) and PHB (Thermo Fisher Scientific Waltham, MA, USA, dilution 1:100). Following this, a secondary antibody (Vectastain Elite ABC Kit, Universal, Vector Laboratories Inc.) was applied. Next, the slides were incubated with avidin-biotin-peroxidase complex (Vectastain Elite ABC Kit) and developed with Vector NovaRED kit (Vector Laboratories Inc.) for 5 min. The slides were counterstained with Harris haematoxylin and mounted with Permount (Biomeda, Foster City, CA, USA). Percentages of nuclear RelA/p65 and p53, cytoplasmic TNFR1 and TRAIL, and nuclear/cytoplasmic PHB-positive cells were obtained blindly for each case at least 10 representative high-power fields (40×) by two of the authors (LDP and LNR). For statistical purposes, the samples were scored as follows: -, no stained cells; +, weak or moderate staining in less than 25% positive cells; ++, moderate to strong staining in 25-50% positive cells; and ++++, strong staining in more than 50% positive cells.

Southwestern histochemistry analysis
Non-radioactive in situ detection of NFκB in paraffin-embedded liver tissue preparations was performed using the Southwestern histochemistry method, with digoxigenin labelling and detection kits (Roche Applied Science, Indianapolis, USA). Briefly, synthetic sense DNAs (Imprint Genetics Corporation, Hialeah, USA), which contain sequences of NFκB, were used as probes. After annealing with the complementary sequence, the DNA probe was labelled with digoxigenin.
Table 1: Clinicopathologic variables of NL, CIR, HCV, and HCC

<table>
<thead>
<tr>
<th>Clinicopathologic variables</th>
<th>Etiology (% cases)</th>
<th>NL (n = 20)</th>
<th>HCV (n = 30)</th>
<th>CIR (n = 60)</th>
<th>HCC (n = 60)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.5530</td>
</tr>
<tr>
<td>≤ 50</td>
<td>0</td>
<td>40</td>
<td>20</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 50</td>
<td>100</td>
<td>60</td>
<td>80</td>
<td>65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.4116</td>
</tr>
<tr>
<td>Male</td>
<td>60</td>
<td>80</td>
<td>70</td>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>40</td>
<td>20</td>
<td>30</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0001</td>
</tr>
<tr>
<td>Absence</td>
<td>100</td>
<td>100</td>
<td>0</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presence</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>97</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum AFP (µg/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0001</td>
</tr>
<tr>
<td>≤ 20</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 20</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>60</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NL: normal liver; CIR: cirrhosis; HCV: hepatitis C virus; HCC: hepatocellular carcinoma

The percentage of NFκB-positive cells was obtained blindly for each case, at least 10 representative high-power fields (40×) by two of the authors (LDP and LNR). For statistical purposes, the samples were scored similarly as was presented in the immunohistochemistry section.[18]

**TUNEL assay**

Paraffin-embedded liver tissue sections were deparaffinised and incubated with 20 µg/mL proteinase K (Promega Corporation, Madison, USA). A DeadEnd peroxidase in situ apoptosis detection kit (DeadEnd TUNEL; Promega Corporation) was used for transferase-mediated dUTP-biotin nick-end labelling (TUNEL) staining. The percentage of TUNEL-positive cells was obtained blindly, for each case at least 10 representative high-power fields (40×) by two of the authors (LDP and LNR). For statistical purposes, the samples were scored similarly as was presented in the immunohistochemistry section.[18]

**Statistical evaluation**

Statistical analysis was performed using GraphPad Prism v4.0 software (GraphPad Software, Inc., San Diego, CA). Association between the expression of TNFR1, TRAIL, NFκB, RelA/p65, p53, PHB, and TUNEL and histologic variables was determined by Fisher’s exact test (2 groups) or a chi-square test (3 or more groups). One-way analysis of variance followed by Dunn’s post-test was also performed. All tests were two-tailed, and P < 0.05 was considered significant.

**RESULTS**

**Study tissue specimens**

The most relevant data concerning clinic and pathological variables was the occurrence of cirrhosis or viral hepatitis in almost all HCC cases, as well as absence of cirrhosis or other inflammatory conditions in the normal liver (P = 0.0001). Additionally, the level serum α-fetoprotein was > 20 µg/L in the majority of HCC cases, but ≤ 20 µg/L in the other types (P = 0.0001) [Table 1].

**Expression and clinicopathological features**

Table 2 summarizes the comparative TNFR1, TRAIL, NFκB, nuclear RelA/p65, p53, nuclear PHB and cytoplasmic PHB and TUNEL expression by HCC, CIR, HCV, and NL.

TNFR1 expression was higher in CIR [Figure 1C] in comparison to HCC [Figure 1D] and HCV [Figure 1B] (P = 0.0294 and P = 0.0037, respectively), as well as in HCV compared to NL [Figure 1A] (P = 0.0313) [Figure 1Q]. TRAIL expression was amplified in HCC [Figure 1H] compared to CIR [Figure 1G] and HCV [Figure 1F] (P = 0.0377 and P = 0.0371, respectively), as well as in HCV in relation to NL [Figure 1E] (P = 0.0462) [Figure 1R].

NFκB expression was increased in CIR [Figure 1K] in comparison to HCC [Figure 1L] (P = 0.0464). NFκB expression was also higher in CIR compared to HCV [Figure 1J] (P = 0.0031), as well as in HCV in relation to NL [Figure 1D] (P = 0.0477) [Figure 1S]. In a pattern similar to that of NFκB, nuclear RelA/p65 expression was increased in CIR [Figure 1O] compared to HCC [Figure 1P] and HCV [Figure 1N] (P = 0.0228 and P = 0.0426, respectively), as well as in HCV relative to NL [Figure 1M] (P = 0.0288) [Figure 1S].

Since p53 expression was almost solely found in HCC [Figure 2D], this group presented a higher p53 expression relative to NL [Figure 2A], HCV [Figure 2B], and CIR [Figure 2C] (P = 0.011, P = 0.014 and P = 0.0013, respectively). However, no difference in p53 expression was observed between CIR and HCV (P = 0.9421), as well as in HCV in relation to NL (P = 0.9421) [Figure 2M].

Cytoplasmic PHB expression was augmented in CIR [Figure 2G] in relation to HCC [Figure 2H] (P = 0.0001), whereas PHB cytoplasmic expression was similar between CIR and HCV [Figure 2F] (P = 0.4468). PHB cytoplasmic expression was increased in HCV, CIR, and HCC in comparison to NL [Figure 2E] (P = 0.0088). Because PHB nuclear expression was almost exclusively observed in HCC, this group presented a higher PHB nuclear expression in contrast to CIR, HCV, and NL (P = 0.0041, P = 0.0011 and P = 0.0011, respectively) [Figure 2N].
The percentage of apoptosis was increased in HCC [Figure 2L] in contrast to CIR [Figure 2K] and HCV [Figure 2J] ($P = 0.0054$ and $P = 0.0217$, respectively). Moreover, the percentage of apoptosis was increased in HCV in relation to NL [Figure 2I] ($P = 0.0161$).

**DISCUSSION**

The findings of the present study reveal the importance of p53 and PHB participation in human hepatic cancer development, which is dependent on different pathogenic mechanisms of the tumour microenvironment.

TNF$\alpha$ cytokine is increased in patients with chronic HCV infection.\(^{[9]}\) TNF$\alpha$ and TNF-receptors levels are augmented during chronic HCV infection and result in disease progression.\(^{[9]}\) Similarly, we found a progressive increase of TNFR1 expression in cases of HCV and CIR in comparison to NL. Indeed, TNF$\alpha$...
Figure 1: Comparative expression of TNFR1 (immunohistochemistry, ×200), TRAIL (immunohistochemistry, ×200), NFkB (Southwestern histochemistry, ×200) and RelA/p65 (immunohistochemistry, ×200) by NL, HCV, CIR and HCC. A: low expression of TNFR1 in NL; B: increased expression of TNFR1 in HCV; C: high expression of TNFR1 in CIR; D: strong expression of TNFR1 in HCC; E: minimal expression of TRAIL in NL; F: increased expression of TRAIL in HCV; G: augmented expression of TRAIL in CIR; H: high expression of TRAIL in HCC; I: low expression of NFkB in NL; J: high expression of NFkB in HCV; K: marked expression of NFkB in CIR; L: increased expression of NFkB in HCC; M: minor expression of RelA/p65 in NL; N: increased expression of RelA/p65 in HCV; O: evident expression of RelA/p65 in CIR; P: high expression of RelA/p65 in HCC; (Q, R, S) comparison of the TNFR1 (Q), TRAIL (R), NFkB and RelA/p65 (S) labeling scores by NL, HCV, CIR and HCC. *P < 0.05 vs. NL; **P < 0.05 vs. HCV; ***P < 0.05 vs. CIR. TNFR1: tumor necrosis factor receptor-1; TRAIL: TNF-related apoptosis-inducing ligand; NFkB: nuclear factor kappa B; NL: normal liver; CIR: cirrhosis; HCV: hepatitis C virus; HCC: hepatocellular carcinoma
Proinflammatory stimuli can be responsible for NFκB activation, which results in protection of hepatocytes from apoptosis.\[^9\] Moreover, the HCV core protein potentiates NFκB activation and chronically activated NFκB leads to infected hepatocytes survival and consequent HCV infection persistence.\[^{21}\]

In the present study, RelA/p65 nuclear labelling

<table>
<thead>
<tr>
<th></th>
<th>NL</th>
<th>HCV</th>
<th>CIR</th>
<th>HCC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P53</strong></td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>PHB</strong></td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>TUNEL</strong></td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
<td><img src="image11.png" alt="Image" /></td>
<td><img src="image12.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**Figure 2:** Comparative expression of P53 (immunohistochemistry, ×200), PHB (immunohistochemistry, ×400) and TUNEL (immunoassay, ×200) by NL, HCV, CIR and HCC. A: absence of P53 expression in NL; B: low expression of P53 in HCV; C: minor expression of P53 in CIR; D: high nuclear and cytoplasmic expression of P53 in HCC; E: slight cytoplasmic expression of PHB in NL; F: augmented cytoplasmic expression of PHB in HCV; G: high cytoplasmic expression of PHB in CIR; H: strong nuclear and cytoplasmic expression of PHB in HCC; I: slight expression of apoptosis in NL; J: increased expression of apoptosis in HCV; K: augmented expression of apoptosis in CIR; L: marked expression of apoptosis in HCC; (M, N, O) comparison of the P53 (M), cytoplasmic and nuclear PHB (N) and TUNEL (O) labeling scores by NL, HCV, CIR and HCC. *P < 0.05 vs. NL; **P < 0.05 vs. HCV; ***P < 0.05 vs. CIR. PHB: prohibitin; TUNEL: transferase-mediated dUTP-biotin nick-end labelling; NL: normal liver; CIR: cirrhosis; HCV: hepatitis C virus; HCC: hepatocellular carcinoma
Comparison of p53 and prohibitin expression

p53 has been widely considered as a tumor suppressor gene associated with induction of apoptosis in different types of neoplasms, including HCC. Furthermore, p53 is usually less expressed during HCV than in HCC. Accordingly, we found p53 expression almost solely in HCC, without significant changes during chronic liver inflammation. Increased p53 expression was also followed by augmentation of apoptosis in HCC. Moreover, the RelA/p65 subunit can inhibit p53 activation, as well as p53 also suppresses NFkB transcriptional effects. Perhaps during HCV and CIR, the inflammatory stimulus induces an increase of TNFα with consequent NFkB activation and p53 inhibition, which leaked from hepatocytes from apoptosis. Concerning HCC, which present a less evident inflammatory process, TNFα-induced NFkB activation is discrete and, in addition to inhibition of NFkB activation by p53, augments apoptosis. Furthermore, another possible suppressor tumor gene, PHB, has been associated with an increase of p53 activity in the induction of apoptosis in cancer.

The role of PHB, in particular, is not fully understood. There are controversies because both antitumorigenic and protumorigenic functions have been reported for PHB, depending on its subcellular localization. In addition to regulation of various cellular functions, the mitochondrial location of PHB is mainly engaged in reducing damage caused by oxidative stress in the chronic phase of various diseases. In our HCV and CIR samples, we detected a high expression of cytoplasmic PHB, likely due to chronic inflammation associated with these diseases. Moreover, in spite of PHB reducing NFkB activation mediated by TNFα, which permits occurrence of apoptosis, high levels of TNFα can also inhibit tumour suppressor PHB activity during chronic inflammation. This regulatory mechanism may explain increased NFkB activation and higher hepatocytes survival in HCV and CIR in comparison with HCC, despite high cytoplasmic PHB expression in HCV and CIR. In addition, the failure of apoptosis of mutated hepatocytes may represent a primary event in the hepatocarcinogenesis associated with chronic liver disease.

Our data show that PHB expression was exclusively identified as nuclear labelling in HCC. It has been reported that nuclear PHB appears to be essential for regulation of cellular processes such as apoptosis, proliferation, and gene transcription. PHB was also detected in the nucleus associated with retinoblastoma and p53, inducing changes in transcription factors, resulting in cell cycle inhibition and induction of apoptosis. The tumour suppressor action of PHB was associated with nuclear expression in cells of several neoplasms. In agreement, the HCC group presented exclusively a PHB nuclear expression in contrast to CIR and HCV. Because NFkB may be acting as an antiapoptotic mediator, and once inhibited by the action of PHB in HCC, it may increase the rate of apoptosis in these cases.

In conclusion, our results suggest that, in addition to well-understood sequences of proinflammatory events such as TNFα-induced NFkB activation and NFkB/TRAIL pathway-mediated apoptosis, development of human hepatic cancer may be influenced by regulation of p53 and PHB tumor suppressor function. Another possibility would be that expression of p53 and PHB may have been altered as a consequence of an already-established hepatocellular carcinoma. Additional studies are necessary to explain the contradictory mechanisms of the tumour...
Comparison of p53 and prohibitin expression

Authors’ contributions

Casuistic retrieval and samples analysis: L.M. Della Porta
Statistical analysis and writing: F.S. Ramalho
Samples analysis and discussion: C.A. Oliveira
Histological and immunohistochemical preparations
and analysis: D.M. Silva
Southwestern histochemistry and analysis: M.J. Augusto
Paper scientific design and writing: L.N.Z. Ramalho

Financial support and sponsorship

This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) – nº2010/20895-4, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-nº302547/2012-6 and Fundação de Amparo à Fundação de Apoio ao Ensino, Pesquisa e Assistência (FAEPA).

Conflict of interests

There are no conflicts of interests.

Patient consent

Each patient was informed of the study and gave their consent.

Ethics approval

The study was approved by the local Ethics Committee (nº1611/2011).

REFERENCES


